tranylcypromine (parnate) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Tranylcypromine, sold under the brand name Parnate among others, is a monoamine oxidase inhibitor (MAOI). More specifically, tranylcypromine acts as nonselective and irreversible inhibitor of the enzyme monoamine oxidase (MAO). It is used as an antidepressant and anxiolytic agent in the clinical treatment of mood and anxiety disorders, respectively.   Wikipedia

Chemistry

More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.4358 - $6.8806

Australia

$0.5942
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(1r*,2s*)-2-phenylcyclopropan-1-amine | dl-tranylcypromine | pamate | parnate | parstelin | racemic tranylcypromine | (rs)-trans-2-phenylcyclopropylamine | trancyclopromine | tranilcipromina | (±)-trans-2-phenylcyclopropylamine | trans-2-phenylcyclopropylamine | transamine | trans-dl-2-phenylcyclopropylamine | tranylcypromin | tranylcypromine | tranylcypromine hcl | tranylcypromine hydrochloride | tranylcypromine sulfate | tranylcyprominum

Organizations (20)

Research & Development (14)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (14)

Approved Indications (3)


 

Depression (approved 1961)

Depressive Disorder

Depressive Disorder, Major

Experimental Indications - Clinical Trial Phases 1-4 (14)


 

Anxiety Disorders (Phase 3)

Bipolar Disorder (Phase 4)

Dementia (Phase 3)

Depression (Phase 4)

Depressive Disorder ()

Depressive Disorder, Major (Phase 4)

Hypotension, Orthostatic (Phase 1)

Leukemia (Phase 1)

Leukemia, Myeloid, Acute (Phase 1/Phase 2)

Myelodysplastic Syndromes (Phase 1/Phase 2)

Pharmacology (Phase 1)

Psychophysiologic Disorders (Phase 3)

Pure Autonomic Failure (Phase 1)

Schizophrenia (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial Organizations: 14

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue